5 Stocks Trading Under $10 That Could Have Gigantic Upside Potential

Print Email

Chaparral Energy

Shares of this energy company have been obliterated and may hold massive upside potential. Chaparral Energy Inc. (NASDAQ: CHAP) engages in the onshore oil and natural gas acquisition, exploitation, exploration and production. It focuses on deposits of Stack, Meramec and Osage, Oswego and Woodford located in Oklahoma and the Texas Panhandle. As of March 29, 2018, it had estimated potential reserves of one billion barrels of oil equivalent.

Chaparral recently announced that it anticipates 2019 total company production to be between 25,000 and 27,000 barrels of oil equivalent per day, which represents 22% to 32% year-over-year growth. Total Stack production is expected to be between 21,000 and 23,000 barrels of oil equivalent per day, which is a forecast year-over-year growth rate of 45% to 59%. While full-year production will have significant growth, first-quarter production will be affected by the timing of first sales associated with Chaparral’s current spacing tests and remaining drilling joint venture wells.

Stifel’s Buy rating comes with a gigantic $22 price target. That is even higher than the huge $20.75 consensus estimate. Shares ended the week at $4.24 apiece.

Noodles & Company

This stock has been a roller-coaster ride but also has giant upside potential. Noodles & Co. (NASDAQ: NDLS) operates in the restaurant industry, offering lunch and dinner meals. The company serves a variety of cooked-to-order dishes, including noodles and pasta, soups, salads, sandwiches and appetizers.

The company claims it serves noodles your way, from noodles and flavors that you know and love to new ones you’re about to discover for the first time. From indulgent Wisconsin Mac & Cheese to good-for-you Zoodles, Noodles serves a world of flavor in every bowl. With more than 450 restaurants and 10,000 employees, it is expected to report earnings next week.

Jefferies recently upgraded the stock from Hold to Buy with an $11 price objective. The posted consensus target was last seen at $11.43, and the stock was changing hands at $7.21 on last look.

Seres Therapeutics

This small-cap biotech stock could explode higher. Seres Therapeutics Inc. (NASDAQ: MCRB) is a microbiome therapeutics platform company that engages in the development of biological drugs. It focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

When it released earnings recently, the company also noted the initiation of a SER-401 Phase 1b study in patients with metastatic melanoma. SER-401 is an oral microbiome therapeutic candidate sourced from healthy individuals identified to have a microbiome bacterial signature similar to that observed in immunotherapy responders.

The Phase 1b study, conducted in collaboration with The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy, will evaluate the potential for SER-401 to augment response to anti-PD-1 checkpoint inhibitor therapy.

The $14 Oppenheimer price target accompanies a Buy rating. The consensus target is $13.60, and shares were last seen trading at $5.11.

I'm interested in the Newsletter

These are five stocks for aggressive accounts looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.